Clinical Improvement and Recovery of Systolic Function in Chronic Triple-Vessel Coronary Artery Disease with Controlled Diabetes Mellitus After Long-Term Conservative Management and Adjunctive Hydrogen Nanobubble Infusion Therapy: A Case Report
Ricki Yudhanata, Christyanita P. Ekasari, Subagjo Subagjo · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In Case Presentation: Coronary angiography demonstrated triple-vessel disease, and CABG was recommended, but the patient declined surgery, after 12 sessions of Hydrogen Nanobubble Infusion Therapy, the patient reported symptomatic improvement, and a follow-up reevaluation reportedly documented an increase in left ventricular ejection fraction from approximately 52% to 62%. These findings add human evidence supporting molecular hydrogen's therapeutic potential for recovery after myocardial infarction.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in Case Presentation: Coronary angiography demonstrated triple-vessel disease, and CABG was recommended, but the patient declined surgery. After 12 sessions of Hydrogen Nanobubble Infusion Therapy, the patient reported symptomatic improvement, and a follow-up reevaluation reportedly documented an increase in left ventricular ejection fraction from approximately 52% to 62%.
What the Researchers Studied
The researchers studied Case Presentation: Coronary angiography demonstrated triple-vessel disease, and CABG was recommended, but the patient declined surgery.
What Effects Did Molecular Hydrogen Have?
After 12 sessions of Hydrogen Nanobubble Infusion Therapy, the patient reported symptomatic improvement, and a follow-up reevaluation reportedly documented an increase in left ventricular ejection fraction from approximately 52% to 62%. The authors concluded that the post-treatment symptomatic improvement and reported increase in systolic performance are interesting, but causality cannot be established from a single case.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for recovery after myocardial infarction and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was Case Presentation: Coronary angiography demonstrated triple-vessel disease, and CABG was recommended, but the patient declined surgery.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://www.preprints.org/manuscript/202609.0114/v1.